Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 12/20 | 0.38 |
| ▸ | TACR1 | P25103 | 12/20 | 0.38 |
| ▸ | TAC3 | Q9UHF0 | 5/20 | 0.38 |
| ▸ | TACR3 | P29371 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972572 | 0.82 | TACR1 (0.44) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1968840 | 0.80 | TACR1 (0.42) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1971001 | 0.79 | SLC6A4 (0.37) | TACR2TACR1PGRSLC6A2SLC6A4 | |
| SCHEMBL1974091 | 0.77 | TACR1 (0.49) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL15463536 | 0.76 | TACR1 (0.56) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL4002700 | 0.76 | TACR1 (0.56) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL4150577 | 0.76 | TACR1 (0.56) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1971048 | 0.74 | TACR1 (0.48) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1973935 | 0.74 | TACR1 (0.43) | TACR2TACR1TAC3TACR3 | |
| SCHEMBL1969398 | 0.73 | LMNA (0.37) | TACR2TACR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | TACR2 29/4885TACR1 13/4885TAC3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.